“I appreciate this! Companies that have become ‘forgotten’ over a period of time for lack of mainstream media emphasis; also nearly forgotten by analysts and the widespread ability of popular digital influencers to repeat the same things over and over again – always in the same direction I seek on this platform exactly the opposite: to expose what is still hidden from the eyes of the majority.”
With a devaluation of 76% since May 2018, this company has already grown absurdly in its pipeline of innovative treatments against special cancers and urological diseases, including one of the treatments already approved by the FDA (Food and Drug Administration is a federal agency of the Department Health and Human Services Department) and being widely marketed. The great differential in its innovative treatments stands out for its non-invasive feature (WITHOUT SURGERY), especially in the urological system.
The company, founded in 2004, has a market value of approximately $200 million dollars, but with just the first treatment approved this year, it has already secured revenue of $13 million in the last quarter. Therefore, possibly, its stock values tend to have a STRONG valuation in the medium and long term.
Keep reading to find out what THIS company IS and about the possible return OF YOUR ACTIONS.
Subscribe to get access
Read ALL content by signing here.